These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21362129)

  • 1. Migration of bone marrow-derived cells and improved perfusion after treatment with erythropoietin in a murine model of myocardial infarction.
    Brunner S; Huber BC; Weinberger T; Vallaster M; Wollenweber T; Gerbitz A; Hacker M; Franz WM
    J Cell Mol Med; 2012 Jan; 16(1):152-9. PubMed ID: 21362129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis.
    Brunner S; Winogradow J; Huber BC; Zaruba MM; Fischer R; David R; Assmann G; Herbach N; Wanke R; Mueller-Hoecker J; Franz WM
    FASEB J; 2009 Feb; 23(2):351-61. PubMed ID: 18827024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G-CSF treatment after myocardial infarction: impact on bone marrow-derived vs cardiac progenitor cells.
    Brunner S; Huber BC; Fischer R; Groebner M; Hacker M; David R; Zaruba MM; Vallaster M; Rischpler C; Wilke A; Gerbitz A; Franz WM
    Exp Hematol; 2008 Jun; 36(6):695-702. PubMed ID: 18346841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of parathyroid hormone and G-CSF treatment after myocardial infarction on perfusion and stem cell homing.
    Huber BC; Fischer R; Brunner S; Groebner M; Rischpler C; Segeth A; Zaruba MM; Wollenweber T; Hacker M; Franz WM
    Am J Physiol Heart Circ Physiol; 2010 May; 298(5):H1466-71. PubMed ID: 20207820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin improves the efficiency of endothelial progenitor cell therapy after myocardial infarction in mice: effects on transplanted cell survival and autologous endothelial progenitor cell mobilization.
    Cheng Y; Hu R; Lv L; Ling L; Jiang S
    J Surg Res; 2012 Jul; 176(1):e47-55. PubMed ID: 22595018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous bone-marrow-derived stem cells contribute only a small proportion of regenerated myocardium in the acute infarction model.
    Fukuhara S; Tomita S; Nakatani T; Yutani C; Kitamura S
    J Heart Lung Transplant; 2005 Jan; 24(1):67-72. PubMed ID: 15653382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization.
    Westenbrink BD; Lipsic E; van der Meer P; van der Harst P; Oeseburg H; Du Marchie Sarvaas GJ; Koster J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
    Eur Heart J; 2007 Aug; 28(16):2018-27. PubMed ID: 17576662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization.
    Heeschen C; Aicher A; Lehmann R; Fichtlscherer S; Vasa M; Urbich C; Mildner-Rihm C; Martin H; Zeiher AM; Dimmeler S
    Blood; 2003 Aug; 102(4):1340-6. PubMed ID: 12702503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model.
    Klopsch C; Furlani D; Gäbel R; Li W; Pittermann E; Ugurlucan M; Kundt G; Zingler C; Titze U; Wang W; Ong LL; Wagner K; Li RK; Ma N; Steinhoff G
    J Cell Mol Med; 2009 Apr; 13(4):664-79. PubMed ID: 19449462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin enhances the angiogenic potency of autologous bone marrow stromal cells in a rat model of myocardial infarction.
    Zhang D; Zhang F; Zhang Y; Gao X; Li C; Ma W; Cao K
    Cardiology; 2007; 108(4):228-36. PubMed ID: 17106196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs.
    Hirata A; Minamino T; Asanuma H; Fujita M; Wakeno M; Myoishi M; Tsukamoto O; Okada K; Koyama H; Komamura K; Takashima S; Shinozaki Y; Mori H; Shiraga M; Kitakaze M; Hori M
    J Am Coll Cardiol; 2006 Jul; 48(1):176-84. PubMed ID: 16814664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin priming improves the vasculogenic potential of G-CSF mobilized human peripheral blood mononuclear cells.
    Kang J; Yun JY; Hur J; Kang JA; Choi JI; Ko SB; Lee J; Kim JY; Hwang IC; Park YB; Kim HS
    Cardiovasc Res; 2014 Oct; 104(1):171-82. PubMed ID: 25082847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Migration of bone marrow-derived cells for endogenous repair in a new tail-looping disc degeneration model in the mouse: a pilot study.
    Sakai D; Nishimura K; Tanaka M; Nakajima D; Grad S; Alini M; Kawada H; Ando K; Mochida J
    Spine J; 2015 Jun; 15(6):1356-65. PubMed ID: 25459743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart.
    Huber BC; Brunner S; Segeth A; Nathan P; Fischer R; Zaruba MM; Vallaster M; Theiss HD; David R; Gerbitz A; Franz WM
    Cardiovasc Res; 2011 Jun; 90(3):529-37. PubMed ID: 21245057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glyoxalase-1 overexpression in bone marrow cells reverses defective neovascularization in STZ-induced diabetic mice.
    Vulesevic B; McNeill B; Geoffrion M; Kuraitis D; McBane JE; Lochhead M; Vanderhyden BC; Korbutt GS; Milne RW; Suuronen EJ
    Cardiovasc Res; 2014 Feb; 101(2):306-16. PubMed ID: 24259499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of erythropoietin on the migration of bone marrow-derived mesenchymal stem cells to the acute kidney injury microenvironment.
    Liu N; Tian J; Cheng J; Zhang J
    Exp Cell Res; 2013 Aug; 319(13):2019-2027. PubMed ID: 23624354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin stimulates normal endothelial progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia.
    Westenbrink BD; Oeseburg H; Kleijn L; van der Harst P; Belonje AM; Voors AA; Schoemaker RG; de Boer RA; van Veldhuisen DJ; van Gilst WH
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):265-74. PubMed ID: 18327705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of cardiac hypertrophy by G-CSF is associated with enhanced migration of bone marrow-derived cells.
    Huber BC; Beetz NL; Laskowski A; Ziegler T; Grabmaier U; Kupatt C; Herbach N; Wanke R; Franz WM; Massberg S; Brunner S
    J Cell Mol Med; 2015 May; 19(5):1033-41. PubMed ID: 25754690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Erythropoietin enhances the therapy potency of autologous bone marrow stromal cells in a rat heart infarction model via phosphatidylinositol-3-kinase/Akt pathway].
    Zhang DG; Zhang FM; Zhang YQ; Zhou F; Gao X; Li CF; Cao KJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):912-6. PubMed ID: 17217721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naoxintong inhibits myocardial infarction injury by VEGF/eNOS signaling-mediated neovascularization.
    Wang H; Qiu L; Ma Y; Zhang L; Chen L; Li C; Geng X; You X; Gao X
    J Ethnopharmacol; 2017 Sep; 209():13-23. PubMed ID: 28669772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.